Compare Medpace Holdings Inc (MEDP) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs S&P500 ETF — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while S&P500 ETF trades at $778.54 (market cap $821.54B). The key difference: S&P500 ETF is far larger — about 48.8× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 40,070,358). Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and S&P500 ETF for 205 Days on average.
| MEDP | SPY | |
|---|---|---|
Market Cap | $16.82B | $821.54B |
Volume | 223,093 | 40,070,358 |
Sector | Health | — |
52-Week High | $630.19 | $779.14 |
52-Week Low | $393.42 | $631.99 |
Typical Hold Time | 14 Days | 205 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
SPY, tracking the S&P 500, trades at $773.97, down 0.42% over 24 hours, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The ETF is near its pivot point of $774, with support at $771 and resistance at $777. Recent news highlights mixed sentiment, with some articles pointing to strong profit growth in 2026 but expectations of a slowdown in 2027, while others discuss defensive positioning and valuation concerns amid market volatility.
The outlook for SPY remains tied to broader market dynamics, with potential upside from continued corporate earnings growth but risks from economic slowdowns and elevated valuations. Investors face opportunities from historical year-end rallies cited by analysts, yet must weigh risks like margin debt warnings and profit growth deceleration. Key factors include upcoming economic data and institutional flows influencing near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
